The estimated Net Worth of Kevin E Lofton is at least $1.67 Milión dollars as of 9 March 2023. Mr. Lofton owns over 8,442 units of Gilead Sciences stock worth over $683,295 and over the last 15 years he sold GILD stock worth over $573,790. In addition, he makes $414,977 as Lead Independent Director at Gilead Sciences.
Sign up
Mr. Lofton GILD stock SEC Form 4 insiders trading
Kevin has made over 10 trades of the Gilead Sciences stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 8,442 units of GILD stock worth $442,192 on 9 March 2023.
The largest trade he's ever made was exercising 21,720 units of Gilead Sciences stock on 24 February 2020 worth over $426,364. On average, Kevin trades about 1,215 units every 26 days since 2009. As of 9 March 2023 he still owns at least 8,442 units of Gilead Sciences stock.
You can see the complete history of Mr. Lofton stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kevin Lofton biography
Kevin E. Lofton has been appointed as Lead Independent Director of the Company effective 5/2020. Mr. Lofton is the Chief Executive Officer (CEO) of Common Spirit Health (CSH), a system of hospitals and other care centers in 21 states that resulted from the merger of Catholic Health Initiatives (CHI) and Dignity Health. Mr. Lofton plans to retire from this role on June 30, 2020. Prior to leading CSH, he served as the CEO of CHI from 2003 to 2019. Mr. Lofton also served as CEO of two university hospitals, the UAB Hospital and Howard University Hospital. In 2014, he received an honorary Doctor of Humanities in Medicine degree from the Baylor College of Medicine and the Healthcare Financial Management Association’s Richard L. Clarke Board of Directors Award. He is recognized for his extensive work in the area of heath care management, eliminating health disparities and creating healthier communities. Mr. Lofton was the chairman of the American Hospital Association in 2007. He also serves on the board of directors of Rite Aid Corporation.
What is the salary of Kevin Lofton?
As the Lead Independent Director of Gilead Sciences, the total compensation of Kevin Lofton at Gilead Sciences is $414,977. There are 12 executives at Gilead Sciences getting paid more, with Daniel O'Day having the highest compensation of $29,107,900.
How old is Kevin Lofton?
Kevin Lofton is 65, he's been the Lead Independent Director of Gilead Sciences since 2020. There are 6 older and 18 younger executives at Gilead Sciences. The oldest executive at Gilead Sciences, Inc. is Richard Whitley, 74, who is the Independent Director.
What's Kevin Lofton's mailing address?
Kevin's mailing address filed with the SEC is C/O MEDTRONIC, 710 MEDTRONIC PARKWAY, MINNEAPOLIS, MN, 55432.
Insiders trading at Gilead Sciences
Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger a John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.
What does Gilead Sciences do?
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
What does Gilead Sciences's logo look like?
Complete history of Mr. Lofton stock trades at Gilead Sciences, Medtronic Plc a Rite Aid
Gilead Sciences executives and stock owners
Gilead Sciences executives and other stock owners filed with the SEC include:
-
Daniel O'Day,
Chairman of the Board, Chief Executive Officer -
Johanna Mercier,
Chief Commercial Officer -
Daniel P. O'Day,
Chairman & CEO -
Andrew Dickinson,
Chief Financial Officer, Executive Vice President -
Brett Pletcher,
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary -
Johanna Mercier,
Chief Commercial Officer -
Dr. Merdad V. Parsey M.D., Ph.D.,
Chief Medical Officer -
Merdad Parsey,
Chief Medical Officer -
Brett A. Pletcher,
Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. -
Andrew D. Dickinson,
Exec. VP & CFO -
Per Wold-Olsen,
Independent Director -
Richard Whitley,
Independent Director -
Kelly Kramer,
Independent Director -
Kevin Lofton,
Lead Independent Director -
Harish Manwani,
Independent Director -
Jacqueline Barton,
Independent Director -
Sandra Horning,
Independent Director -
Anthony Welters,
Director -
Javier Rodriguez,
Director -
Michael Quigley,
Senior Vice President - Research Biology -
Linda Higgins,
Senior Vice President - Head of External Innovation -
Jyoti Mehra,
Executive Vice President of Human Resources -
Dr. Linda Slanec Higgins Ph.D.,
Sr. VP & Head of External Innovation -
Jyoti K. Mehra,
Exec. VP of HR -
Deborah H. Telman,
Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. -
Dr. Diana M. Brainard M.D.,
Sr. VP of HIV & Emerging Viral Infections -
Dr. Taiyin Yang,
Exec. VP of Pharmaceutical Devel. & Manufacturing -
Jacquie Ross C.F.A.,
VP of Investor Relations -
Diane E. Wilfong,
Sr. VP, Corp. Controller & Chief Accounting Officer -
John Francis Cogan,
Director -
John W Madigan,
Director -
Robin L Washington,
SVP, CFO -
Norbert W Bischofberger,
SVP, Research -
James R Meyers,
SVP Comm Ops North America -
Nicholas G Moore,
Director -
Gayle E Wilson,
Director -
Kevin Young,
EVP, Commercial Operations -
Laura Hamill,
EVP, Worldwide Commercial Ops -
Carla A Hills,
Director -
Etienne Davignon,
Director -
Paul Rutherford Carter,
EVP Commercial Ops -
John C Martin,
President and CEO -
John F Milligan,
EVP, Chief Financial Officer -
John G Mc Hutchison,
Chief Scientific Off/HeadR&D -
James M Denny,
Director -
Gordon Earle Moore,
Director -
Kristen Metza,
SVP, Human Resources -
Gregg H Alton,
SVP, General Counsel -
Paul Berg,
Director -
Louis G Lange,
EVP Cardiovascular Therapeutic -
Taiyin Yang,
SVP, Pharm Dev & Mfg -
William A Lee,
SVP Research and PPD -
Anthony Caracciolo,
SVP -
Caroline Dorsa,
SVP, Chief Financial Officer -
John J Toole,
SVP -
George P Shultz,
Director -
Alan Bruce Montgomery,
SVP, Respiratory Therapeutics -
Michael K Inouye,
SVP -
Mark L Perry,
EVP Operations -
Cordell W Hull,
Director -
Diane E. Wilfong,
SVP, Controller & CAO -
Sandra Patterson,
SVP, Controllership -
Jeffrey Bluestone,
Director -
Deborah H Telman,
EVP, Corporate Affairs & GC -
Ted W Love,
Director